secwatch.observer — SEC 8-K summary
======================================

Issuer:     KYNTRA BIO, INC. (KYNB)
CIK:        0000921299
Form:       8-K
Filed at:   2026-08-31T21:18:23+00:00
Accession:  0001193125-26-377059
Event type: debt
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kyntra Bio cuts royalty financing cap from $125M to $65M; pays $42.6M upfront
-----------------------------------------------------------------------------

- Max payments under royalty financing cut from $125M to $65M; $42.6M accelerated payment brings total paid to $50M, full return of investor capital.
- Remaining $15M cap paid from 50% of Astellas EVRENZO revenue (ex-Japan); after cap, Kyntra retains all royalties.
- FibroGen Europe bankruptcy settled for ~$0.1M vs $19.2M obligations; combined liability reduction ~$80M.
- Pro forma cash $53.1M as of June 30, 2026; cash runway into Q4 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921299/000119312526377059/0001193125-26-377059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921299/000119312526377059/kynb-20260831.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-377059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer